According to researchers, the GP2 + GM-CSF vaccine is safe and stimulates an immunologic response when administered concurrently with trastuzumab patients with breast cancer. An ongoing phase II trial is evaluating the efficacy of combining a CD8 T-cell-eliciting vaccine with trastuzumab in HER2-positive breast cancer patients.
Ann Surg Oncol